Page 51 - 22-0424

The International Journal of the Royal Society of Thailand
Volume XI - 2019

& Human Services. USA. Precision Medicine [Internet]. 2019 May 14 [cited
2021 Mar 10]. Available from: https://ghr.nlm.nih.gov/

McAllister P. Monoclonal antibodies and migraine: what the neurologist needs
to know. Pract Neurol. 2017;18–22.

Mendell JR, Al-Zaidy S, Shell AR, Arnold W, Rodino-Klapac L, Prior T, et al.
Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl
J Med. 2017;377:1713–1722. doi:10.1056/NEJMoa1706198.

Mendell JR, Goemans N, Lowes LP, Alfano LN, Berry K, Shao J, et al. Longitudinal
effect of eteplirsen versus historical control on ambulation in Duchenne
muscular dystrophy. Ann Neurol. 2016 ;79:257–271. doi:10.1002/ana.24555.

Mercuri E, Darras B, Chiriboga C, Day J, Campbell C, Connolly A, et al. Nusinersen
versus sham control in later-onset spinal muscular atrophy. N Engl J Med.
2018;378(7):625–635. doi:10.1056/NEJMoa1710504.

Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas D, et al. European
headache federation guideline on the use of monoclonal antibodies acting
on the calcitonin gene related peptide or its receptor for migraine prevention.
J Headache Pain. 2019;6:20. doi:10.1186/s10194-018-0955-y.

Strafella C, Caputo V, Galota M, Zampatti S, Marella G, Mauriello S, et al. Application
of precision medicine in neurodegenerative diseases. Front Neurol.
2018;9:701. doi:10.3389/fneur.2018.00701.

Tan L, Jiang T, Tan L, Yu J. Toward precision medicine in neurological diseases.
Ann Transl Med. 2016;4(6):104. doi:10.21037/atm.2016.03.26.

The personalized medicine report 2017. Opportunity, challenges and the future
[Internet]. Washington: The Personalized medicine coalition; 2017 [cited
2021 Mar 10. Available from: http://www.personalizedmedicinecoalition.
org/ Userfiles / PMC-Corporate/file/PMC_The_Personalized_Medicine_
Report_ Opportunity_Challenges_and_the_Future.pdf
Thomas K. Costly drug for fatal muscular disease wins FDA approval [Internet].

New York: The New York Times: 2016 [cited 2021 Mar 10]. Available
from: https://www.fda.gov/news-events/press-announcements/fda-
approves-first-drug-spinal-muscular-atrophy

45
Kongkiat Kulkantrakorn

11/7/2565 BE 13:27
_22-0424(037-046)5.indd 45
_22-0424(037-046)5.indd 45 11/7/2565 BE 13:27